Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P05113

UPID:
IL5_HUMAN

ALTERNATIVE NAMES:
B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor

ALTERNATIVE UPACC:
P05113; Q13840

BACKGROUND:
Interleukin-5, known for its alternative names such as B-cell differentiation factor I and Eosinophil differentiation factor, is a pivotal cytokine in immune regulation. It targets eosinophils and B-cells, promoting their growth, differentiation, and function. The action of IL-5 is mediated through a specific receptor complex, leading to the activation of signaling pathways that include RAS-MAPK and JAK-STAT5, essential for cellular responses.

THERAPEUTIC SIGNIFICANCE:
The intricate role of Interleukin-5 in immune system modulation presents a promising avenue for developing novel therapeutic approaches aimed at diseases involving eosinophils and B-cells.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.